LY249543 disodium | lometrexol S-isomer | CAS#106400-18-4 | antimetabolite

MedKoo Cat#: 407841 | Name: LY249543 disodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LY249543, the S-isomer of lometrexol, is a Methylenetetrahydrofolate Dehydrogenase/Cycl inhibitor. Lometrexol is a folate analog antimetabolite with antineoplastic activity.

Chemical Structure

LY249543 disodium

CAS#106400-18-4

Theoretical Analysis

MedKoo Cat#: 407841

Name: LY249543 disodium

CAS#: 106400-18-4

Chemical Formula: C21H23N5Na2O6

Exact Mass: 443.1805

Molecular Weight: 487.42

Elemental Analysis: C, 51.75; H, 4.76; N, 14.37; Na, 9.43; O, 19.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

106400-18-4 136208-85-0 120408-07-3 (sodium) 106400-81-1 (free acid)

Synonym

LY249543; LY 249543; LY-249543; LY249543 sodium; S-isomer of lometrexol; DB04322; lometrexol S-isomer.

IUPAC/Chemical Name

disodium (4-(2-((S)-2-amino-4-oxo-1,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)ethyl)benzoyl)-L-glutamate

InChi Key

SVJSWELRJWVPQD-XPTKPXFUSA-L

InChi Code

InChI=1S/C21H25N5O6.2Na/c22-21-25-17-14(19(30)26-21)9-12(10-23-17)2-1-11-3-5-13(6-4-11)18(29)24-15(20(31)32)7-8-16(27)28;;/h3-6,12,15H,1-2,7-10H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30);;/q;2*+1/p-2/t12-,15-;;/m0../s1

SMILES Code

O=C([O-])CC[C@@H](C([O-])=O)NC(C1=CC=C(CC[C@H](CN2)CC3=C2NC(N)=NC3=O)C=C1)=O.[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 487.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol. 2000;45(2):103-10. PubMed PMID: 10663624. 2: Synold TW, Newman EM, Carroll M, Muggia FM, Groshen S, Johnson K, Doroshow JH. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin Cancer Res. 1998 Oct;4(10):2349-55. PubMed PMID: 9796964. 3: Habeck LL, Chay SH, Pohland RC, Worzalla JF, Shih C, Mendelsohn LG. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet. Cancer Chemother Pharmacol. 1998;41(3):201-9. PubMed PMID: 9443636. 4: Turner RN, Aherne GW, Curtin NJ. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. Br J Cancer. 1997;76(10):1300-7. PubMed PMID: 9374375; PubMed Central PMCID: PMC2228144. 5: Muggia FM, Synold TW, Newman EM, Jeffers S, Leichman LP, Doroshow JH, Johnson K, Groshen S. Failure of pretreatment with intravenous folic acid to alter the cumulative hematologic toxicity of lometrexol. J Natl Cancer Inst. 1996 Oct 16;88(20):1495-6. PubMed PMID: 8841028. 6: Synold TW, Xi B, Newman EM, Muggia FM, Doroshow JH. Simple and sensitive method for the quantitative analysis of lometrexol in plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1996 Aug 30;683(2):245-9. PubMed PMID: 8891922. 7: Sessa C, de Jong J, D'Incalci M, Hatty S, Pagani O, Cavalli F. Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue. Clin Cancer Res. 1996 Jul;2(7):1123-7. PubMed PMID: 9816277. 8: Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG, Grindey GB. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res. 1996 May 15;56(10):2331-5. PubMed PMID: 8625328.